Search results
Results from the WOW.Com Content Network
It affects a little over 600 children per year in the United States. Most are diagnosed with stage IV disease, the most advanced form. Even with aggressive therapy, stage IV neuroblastoma carries a poor prognosis, with a three-year survival rate of 30–40%. [7] Compared with other types of cancer, neuroblastoma is rare.
Neuroblastoma comprises 6–10% of all childhood cancers, and 15% of cancer deaths in children. The annual mortality rate is 10 per million children in the 0- to 4-year-old age group, and 4 per million in the 4- to 9-year old age group. [73] The highest number of cases is in the first year of life, and some cases are congenital.
The degree of differentiation of neuroblastoma is correlated to the prognosis, with a wide variety of outcomes (from tumor regression to recurrence and mortality). The standard of care is the use of chemotherapy, surgical resection and radiation, although most aggressive neuroblastomas have demonstrated to be resistant to these therapies.
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment given and many other factors, including country. In general survival rates are improving, although more so for some cancers than others. Survival rate can be measured in several ways, median life expectancy having advantages over others in terms of meaning for ...
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
An example of a Kaplan–Meier plot for two conditions associated with patient survival. The Kaplan–Meier estimator, [1] [2] also known as the product limit estimator, is a non-parametric statistic used to estimate the survival function from lifetime data.
Ganglioneuroblastoma is a variant of neuroblastoma that is surrounded by ganglion cells. It can be difficult to diagnose. [1]